Cargando…
Design and rationale for the DIVERSITY study: An open‐label, randomized study of dabigatran etexilate for pediatric venous thromboembolism
ESSENTIALS: Current standard of care (SOC) for pediatric venous thromboembolism (VTE) has limitations. Dabigatran etexilate (DE) versus SOC will be studied in children with VTE in a phase IIb/III trial. A dosing algorithm for DE in children will be assessed guiding dosing. Valuable data on the safet...
Autores principales: | Albisetti, Manuela, Biss, Branislav, Bomgaars, Lisa, Brandão, Leonardo R., Brueckmann, Martina, Chalmers, Elizabeth, Gropper, Savion, Harper, Ruth, Huang, Fenglei, Luciani, Matteo, Manastirski, Ivan, Mitchell, Lesley G., Tartakovsky, Igor, Wang, Bushi, Halton, Jacqueline M. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055566/ https://www.ncbi.nlm.nih.gov/pubmed/30046738 http://dx.doi.org/10.1002/rth2.12086 |
Ejemplares similares
-
Phase 3, single‐arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design
por: Luciani, Matteo, et al.
Publicado: (2018) -
Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
por: Röshammar, Daniel, et al.
Publicado: (2021) -
Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism
por: Albisetti, Manuela, et al.
Publicado: (2017) -
Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials
por: Mitchell, Lesley G., et al.
Publicado: (2022) -
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia
por: Brandão, Leonardo R., et al.
Publicado: (2022)